Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.

doi:10.1038/s41467-020-17139-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.

Nature communications - 3 Jul 2020

Oh Sejin, Yeom Jeonghun, Cho Hee Jin, Kim Ju-Hwa, Yoon Seon-Jin, Kim Hakhyun, Sa Jason K, Ju Shinyeong, Lee Hwanho, Oh Myung Joon, Lee Wonyeop, Kwon Yumi, Li Honglan, Choi Seunghyuk, Han Jang Hee, Chang Jong Hee, Choi Eunsuk, Kim Jayeon, Her Nam-Gu, Kim Se Hoon, Kang Seok-Gu, Paek Eunok, Nam Do-Hyun, Lee Cheolju, Kim Hyun Seok

Abstract excerpt

The prognostic and therapeutic relevance of molecular subtypes for the most aggressive isocitrate dehydrogenase 1/2 (IDH) wild-type glioblastoma (GBM) is currently limited due to high molecular heterogeneity of the tumors that impedes patient stratification. Here, we describe a distinct binary classification of IDH wild-type GBM tumors derived from a quantitative proteomic analysis of 39 IDH wild-type GBMs as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioblastoma

Share to Isocitrate Dehydrogenase

Share to Mechanistic Target of Rapamycin Complex 1

Share to Mechanistic Target of Rapamycin Complex 2

Share to Morpholines

Share to Proteogenomics

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 32620753
DOI: 10.1038/s41467-020-17139-y
PMCID: PMC7335111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Integrated pharmaco-proteogenomics defines two subgroups in isocitrate dehydrogenase wild-type glioblastoma with prognostic and therapeutic opportunities.PMID 32620753Read ↗

Quantitative proteomic analysis reveals different functional subtypes among IDH-wildtype glioblastomaSemantic proximity Read ↗

Proteogenomic and metabolomic characterization of human glioblastoma.Semantic proximity Read ↗

Quantitative Proteomic Analysis Reveals Different Functional Subtypes among IDH-Wildtype Glioblastoma.Semantic proximity Read ↗

Proteomics separates adult-type diffuse high-grade gliomas in metabolic subgroups independent of 1p/19q codeletion and across IDH mutational status.Semantic proximity Read ↗

Proteome-based insights for IDH-mutant glioma classification.Semantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Multi-scale signaling and tumor evolution in high-grade gliomas.Semantic proximity Read ↗

Integrating Multi-Omics Analysis for Enhanced Diagnosis and Treatment of Glioblastoma: A Comprehensive Data-Driven ApproachSemantic proximity Read ↗

Proteogenomics of glioblastoma associates molecular patterns with survivalSemantic proximity Read ↗

Multi-omics and Pharmacological Characterization of Patient-derived Glioma Cell LinesSemantic proximity Read ↗

Metabolomic profiles of human glioma inform patient survivalSemantic proximity Read ↗

Immune-Suppressed, Not Immune-Cold: HMOX1-CD14-Immunoproteasome Axis and Structure-Guided Combination Pharmacotherapies in Isocitrate Dehydrogenase-Mutant Glioblastoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.